RecruitingNot applicableNCT06192979
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Studying AL amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jin Lu, MD
- Principal Investigator
- Jin LuPeking University People's Hospital
- Intervention
- Daratumumab(drug)
- Enrollment
- 41 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2027
Study locations (6)
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- Capital Medical University Affiliated Fuxing Hospital, Beijing, Beijing Municipality, China
- Beijing Anzhen Hospital, Beijing, Beijing Municipality, China
- Chinese PLA Eastern Theater General Hospital, Nanjing, Jiangsu, China
- Qingdao Municipal Hospital, Qingdao, Shandong, China
- The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an, Shanxi, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06192979 on ClinicalTrials.govOther trials for AL amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06963216A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A.
- RECRUITINGPHASE3NCT07388602A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Sinocelltech Ltd.
- RECRUITINGPHASE1, PHASE2NCT07266116Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNCT07448935One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT07448779Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE2NCT07110844Teclistamab-Daratumumab in AL AmyloidosisSuzanne Lentzsch, MD
- RECRUITINGPHASE1NCT07250269Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGNCT07172243BE.Amycon Biobank & Data Registry UZ LeuvenUniversitaire Ziekenhuizen KU Leuven